E-therapeutics opens in-silico consultancy ops

A systems biology spin-off from Newcastle University has opened up a new consultancy division that will use its in-silico technology to assess the safety and efficacy of new drug candidates. E-therapeutics' technology assesses how a drug will respond to cells as well as other therapeutics. And the start-up has already lined up a lengthy list of drug partners, ranging from GlaxoSmithKline to Mylan Laboratories and Chakra Biotech. E-therapeutics plans to gin some initial revenue from contract research work, later adding licensing deals on new drug development projects.

"Our approach is cost-effective and will permit partners to de-risk investment decisions before they commit the substantial sums required to bring a new drug through clinical development," said CEO Malcolm Young. The biotech company has a therapy for melanoma in pre-clinical tests.

- read the report in the Financial Times

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.